Market Overview

Benchmark Company Reiterates Buy Rating, $87 PT on Analogic Corporation on Ultrasonix Acquisition

Related ALOG
Earnings Scheduled For September 19, 2017
Benzinga's Top Upgrades, Downgrades For August 9, 2017
Analogic Announces Timing for First Quarter —…–8 Earnings Conference Call and Webcast (GuruFocus)

In a report published Friday, Benchmark Company reiterated its Buy rating and $87.00 price target on Analogic Corporation (NASDAQ: ALOG).

Benchmark Company noted, “ALOG announced that the company completed the Ultrasonix Medical acquisition. Ultrasonix Medical is a supplier of advanced ultrasound systems for the point-of-care and general imaging markets with over 5,000 systems installed worldwide. We believe that this acquisition brings multiple benefits including an expanded product line, additional customers for cross-selling opportunities and an expanded sales channel including the sales and marketing infrastructure.”

Analogic Corporation closed on Thursday at $74.00.

Latest Ratings for ALOG

Aug 2017JefferiesInitiates Coverage OnHold
Dec 2016BenchmarkDowngradesBuyHold
Sep 2016Brean CapitalMaintainsBuy

View More Analyst Ratings for ALOG
View the Latest Analyst Ratings

Posted-In: Benchmark CompanyAnalyst Color Reiteration Analyst Ratings


Related Articles (ALOG)

View Comments and Join the Discussion!

Partner Center